TY - JOUR
T1 - Characterization of canine coagulation factor VII and its complex formation with tissue factor:canine-human cross species compatibility
AU - Kristensen, Annemarie Thuri
AU - Knudsen T, Kristensen AT, Sørensen BB, Olsen OH, Stennicke HR, Petersen LC
PY - 2010/8
Y1 - 2010/8
N2 - Background: Canine models have been good predictors of efficacy of hemophilia treatments, including recombinant human coagulation factor (F)VIIa (hFVIIa). However, canine FVIIa and tissue factor (TF) have remained incompletely characterized. Objective: To explore canine-human cross-species FVIIa-TF compatibility in order to strengthen the predictive value of canine models in research on FVIIa and TF. Methods: Canine FVIIa (cFVIIa) and canine TF(1-217) [cTF(1-217)] were produced by recombinant techniques, and canine-human cross-species FVIIa-TF interactions were characterized in vitro. Results: Recombinant cFVIIa and soluble cTF(1-217) were produced and purified to homogeneity. hFVIIa and cFVIIa bound with comparably high affinities to cTF(1-217) (KD = 6.0 ± 0.7 nm and KD = 6.0 ± 0.3 nm, respectively) and to cell surface-expressed cTF (KD = 8.4 ± 0.4 nm and KD = 7.2 ± 1.2 nm, for 125I-labeled hFVIIa and cFVII, respectively). In contrast, cFVIIa bound to human TF (hTF) with decreased affinity, both in solution and on cell surfaces. The decreased binding resulted in reduced activity of cFVIIa in functional assays with hTF(1-209). In direct comparison, cFVIIa was more active than hFVIIa, both in the absence and the presence of cognate TF. Conclusion: The present finding that hFVIIa binds to cTF essentially as it does to hTF substantiates the hypothesis that human FVIIa-TF biology can be reliably recapitulated in canine models on administration of hFVIIa to dogs.
AB - Background: Canine models have been good predictors of efficacy of hemophilia treatments, including recombinant human coagulation factor (F)VIIa (hFVIIa). However, canine FVIIa and tissue factor (TF) have remained incompletely characterized. Objective: To explore canine-human cross-species FVIIa-TF compatibility in order to strengthen the predictive value of canine models in research on FVIIa and TF. Methods: Canine FVIIa (cFVIIa) and canine TF(1-217) [cTF(1-217)] were produced by recombinant techniques, and canine-human cross-species FVIIa-TF interactions were characterized in vitro. Results: Recombinant cFVIIa and soluble cTF(1-217) were produced and purified to homogeneity. hFVIIa and cFVIIa bound with comparably high affinities to cTF(1-217) (KD = 6.0 ± 0.7 nm and KD = 6.0 ± 0.3 nm, respectively) and to cell surface-expressed cTF (KD = 8.4 ± 0.4 nm and KD = 7.2 ± 1.2 nm, for 125I-labeled hFVIIa and cFVII, respectively). In contrast, cFVIIa bound to human TF (hTF) with decreased affinity, both in solution and on cell surfaces. The decreased binding resulted in reduced activity of cFVIIa in functional assays with hTF(1-209). In direct comparison, cFVIIa was more active than hFVIIa, both in the absence and the presence of cognate TF. Conclusion: The present finding that hFVIIa binds to cTF essentially as it does to hTF substantiates the hypothesis that human FVIIa-TF biology can be reliably recapitulated in canine models on administration of hFVIIa to dogs.
M3 - Journal article
SN - 1538-7933
VL - 8
SP - 1763
EP - 1772
JO - Journal of Thrombosis and Haemostasis
JF - Journal of Thrombosis and Haemostasis
IS - 8
ER -